Marvell Is Up 180% in 2026. BofA Sees a $300B Market.
Most of the semiconductor complex opened Monday in the red, dragged down by Anthropic CEO...
Newsletters
Exelixis Gets a Three-Month Wait on Its Next Big Drug
Exelixis shares fell roughly 3.5% in pre-market trading on Friday, September 11, after the company...
J&J’s Surgical Robot Is in Operating Rooms. Its Device Business May Never Be the Same.
Wall Street has spent the better part of two years focused on one problem at...
SoundHound Bought Its Fifth Company. Can This One Deliver Profit?
September 12, 2026 The LivePerson close and a new CFO landed the same day SoundHound...
The Pentagon’s $5B Bet on U.S. Power Gear
September 11, 2026 Washington just made power-grid gear a security priority. Vertiv is building into...
Chime Is Buying Its Own Bank. Now the Real Work Begins.
September 10, 2026 A $590 million deal for Stride turns a seven-year rental into ownership,...
Roivant’s Lung Drug Posted a Record Trial Result. Is 19% Enough?
September 9, 2026 Mosliciguat hit the biggest PVR drop reported in a randomized PH trial....
Nordex Jumps 11% After BofA Upgrade. US Wind Orders Are Why.
September 8, 2026 BofA’s €54 target flags higher margins, backed by a summer of US...
DHT Holdings Turned a $10M Insurance Bill Into Its Best Quarter
September 7, 2026 War-risk premiums at Hormuz have become the real revenue driver for VLCC...
Zcash Hit $1,000. What Does a Buyer Own at That Price?
September 6, 2026 A new Grayscale ETP, a short squeeze, and a privacy coin rally....